| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FQI-2 | CTRPv2 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | BRD-K99006945 | CTRPv2 | pan-cancer | AAC | -0.006 | 0.9 |
| mRNA | BIX-01294 | CTRPv2 | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | BRD-K09344309 | CTRPv2 | pan-cancer | AAC | 0.0067 | 0.9 |
| mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | BRD-K13999467 | CTRPv2 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | CHEMBL374350 | CTRPv2 | pan-cancer | AAC | 0.0026 | 0.9 |